AI-discovered drug displays anti-inflammatory activity in multiple CNS disease models and consistent blood–brain barrier penetration.
This week, AI-native drug discovery leader Insilico Medicine announced its latest partnership, a co-development and licensing deal with Chinese biotech Hygtia Therapeutics to advance a brain-penetrant NLRP3 inhibitor aimed at treating central nervous system disorders. The companies will split worldwide rights to the asset equally, with Insilico eligible to receive up to $66 million in upfront and milestone-based payments, including a $10 million upfront payment.
With an initial focus on Parkinson’s disease, Insilico said will take the drug through investigational new drug submission and Phase 1 clinical trials, while Hygtia will assume responsibility for later-stage clinical development. The collaboration is focused on the NLRP3 inflammasome, a component of the innate immune system that plays a key role in driving neuroinflammation. Dysregulated NLRP3 activity has been linked to the progression of neurodegenerative diseases such as Parkinson’s and Alzheimer’s.
To date, no NLRP3-inhibiting therapies have been approved, and one of the longstanding challenges in the field has been designing molecules that can safely cross the blood–brain barrier while maintaining sufficient potency and tolerability. A small molecule called ISM8969, discovered using Insilico’s generative chemistry platform, has demonstrated the potential to overcome that hurdle. According to the company, the drug’s preclinical data showed anti-inflammatory activity across multiple disease models and consistent penetration of the blood–brain barrier.
“Targeting neuroinflammation via NLRP3 represents a scientifically sound and high-potential approach to treating neurodegenerative and age-related diseases,” said Insilico’s co-CEO Dr Ren Feng. “However, developing a safe molecule with good blood-brain barrier penetration remains a formidable obstacle for drug developers. Through our generative AI platform, we have designed a molecule specifically engineered to overcome this barrier.”
Founded in August 2025, Hygtia is funded and incubated by China’s pharma giant Fosun Pharma. The company said the Insilico partnership represented a “pivotal step” in its global strategy to “expand our innovative neuroscience pipeline through high-quality assets.”
The collaboration is the latest in a series of key developments for Insilico, which recently announced an $888 million oncology drug discovery deal, and raised close to $300 million in its December IPO on the Hong Kong Stock Exchange. With a stated mission to extend human longevity, the company applies generative AI to drug discovery and development, with internal efforts spanning fibrosis, immunology, metabolic disease and beyond.
